Skip to main navigation Skip to search Skip to main content

A preoperative Artificial Intelligence model to estimate cancer-specific mortality in nonmetastatic kidney cancer patients

  • Alessandro Larcher
  • , Alberto Traverso*
  • , Patrick Scuri
  • , Umberto Capitanio
  • , Giacomo Musso
  • , Daniela Canibus
  • , Simone Barbieri
  • , Luca Caivano
  • , Alan Zambello
  • , Marco Denti
  • , Riccardo Campi
  • , Sergio Serni
  • , Salvatore Granata
  • , Anna Palmisano
  • , Davide Vignale
  • , Fracnesco Montorsi
  • , Antonio Esposito
  • , Carlo Tacchetti
  • , Andrea Salonia
  • *Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Surgical resection is the standard treatment for nonmetastatic renal cell carcinoma, yet survival outcomes vary significantly among patients. Current prognostic models lack precision and cannot be applied preoperatively. Here we show the development and validation of a preoperative, interpretable machine learning model to estimate cancer-specific mortality. Using real-world clinical data from 2536 patients and an independent external validation cohort of 580 patients, we combine random survival forests with white-box models to ensure clinical transparency. Our survival tree model relies on exactly eight preoperative features, including tumor size, lymph node involvement, and performance status. We demonstrate that this model outperforms the established GRANT model, achieving a C-index of 0.88 and a Brier score of 0.02 on the external cohort, with notable accuracy in the first year postsurgery. Finally, we provide this tool as a web-based application to facilitate personalized, preoperative risk stratification.
Original languageEnglish
Article number7651
Number of pages10
JournalNature Communications
Volume17
Issue number1
DOIs
Publication statusPublished - 16 Jun 2026

Keywords

  • GUIDELINES
  • DIAGNOSIS

Fingerprint

Dive into the research topics of 'A preoperative Artificial Intelligence model to estimate cancer-specific mortality in nonmetastatic kidney cancer patients'. Together they form a unique fingerprint.

Cite this